Blood cancer therapy SGR-2921 discontinued after patient deaths
Biotech company Schrödinger said it’s discontinuing the development of SGR-2921, an experimental therapy for certain types of blood cancer, following the deaths of…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
Patients needed for trial of CUE-102 for hard-to-treat glioblastoma
Enrollment is now open in a U.S. clinical trial testing the immune-modulating therapy CUE-102 in people with recurrent glioblastoma, an aggressive form of glioma…
Ovarian cancer patients wanted for Phase 3 trial of virus therapy
A Phase 3 clinical trial testing the experimental cancer-killing virus Olvi-Vec in people with hard-to-treat ovarian cancer is recruiting participants. Top-line results from the ongoing…
Sanofi multiple myeloma treatment gets FDA orphan drug status
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an investigational therapy being developed by Sanofi for people with…
FDA fast tracks birelentinib for certain hard-to-treat blood cancers
The U.S. Food and Drug Administration (FDA) granted fast track designation to birelentinib as a potential treatment for certain forms of blood cancer. The…
Committee recommends study of pancreatic cancer vaccine continue
An independent committee has recommended that a clinical trial testing the experimental anticancer vaccine ELI-002 7P in people with pancreatic cancer should continue as…
Darzalex approved in EU to treat smoldering multiple myeloma
Johnson & Johnson‘s Darzalex (daratumumab) is now the first approved treatment for high-risk smoldering multiple myeloma (SMM) in the European Union (EU). SMM…
Scemblix now OK’d in Canada for treating newly diagnosed CML
More people in Canada with the rare blood cancer Ph+ CML — fully, Philadelphia chromosome-positive chronic myeloid leukemia — in the…
Early results ‘extremely positive’ for pancreatic cancer treatment combo
A clinical trial has revealed encouraging results for people with metastatic pancreatic cancer who received Ampligen (rintatolimod) alongside Imfinzi (durvalumab). Nearly two-thirds of…
Voranigo approval urged in EU for treatment of certain brain tumors
A committee of the European Medicines Agency (EMA) is recommending that the daily oral therapy Voranigo (vorasidenib) be approved in the European Union to treat…
